NIKKEI 225
39,103.22 +486.12 (+1.26%) HANG SENG
18,868.71 -326.89 (-1.70%) CRUDE OIL
76.50 -1.07 (-1.38%) GOLD FUTURES
2,334.00 -58.90 (-2.46%) DOW
39,078.72 -592.32 (-1.49%) Bitcoin GBP
52,892.25 -1,920.38 (-3.50%)
Aura Biosciences, Inc. (AURA)
- GlobeNewswire
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that it will host a virtual KOL event on Wednesday, May 29, 2024 at 2:00 PM ET. To register, click here. The event will feature Carol Shields, MD (Wills Eye Hospital), Hakan Demirci, MD (University of Michigan), and Mandeep Sagoo, MB, PhD, FRCS (
- GuruFocus.com
Aura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial Overview
Insights into Aura's Financial Health and Strategic Progress in Clinical Trials
- GlobeNewswire
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, t
